"The 13th Five-Year Plan" Science and Technology Innovation Achievement Exhibition

On the occasion of the 100th anniversary of the founding of the Party, the successful conclusion of the 13th Five-Year Plan and the beginning of the 14th Five-Year Plan, the Ministry of Science and Technology, together with relevant departments, held an exhibition in Beijing on the achievements of the 13th Five-Year Plan in science and technology innovation. The exhibition was held in Beijing. The two projects of heart failure treatment and fully automated cell production line carried out by Help Therapeutics in cooperation with the National Human Genetic Resources Sharing Service Platform were all selected and exhibited together with aerospace satellite technology, land, sea and air exploration technology, high-speed railway technology, ultra-high voltage direct current transmission technology, carbon neutral carbon peak technology and the latest mRNA vaccine, presenting an exciting report card to the top leaders of the country and the general public!

Help Therapeutics leads the way in iPSC heart failure treatment

Through its own production technology, Help Therapeutics has developed the world's leading human-derived induced pluripotent stem cell (iPSC)-based regenerated heart cells and 3D heart tissue, and in 2019 conducted the first clinical treatment study of iPSC-based regenerated human-derived heart cells for heart failure patients worldwide. This product not only solves the shortage of heart transplant donors for heart failure patients, but also greatly reduces the patient This product not only solves the shortage of heart transplant donors for heart failure patients but also greatly reduces the patient's burden in all aspects. The company's iPSC regenerative human-derived heart cell injection is the world's first cell-based drug, and the first clinical study was reported by the top international journal Nature in 2020. heart failure patients.

Fully automated production line, leading the global cellular pharmaceutical 4.0 era

Globally, the technology of stem cell drug development is mostly concentrated in Europe, America and Japan, which is restricted by technology and can only be operated manually, and the quality and yield cannot be guaranteed. Therefore, the selling price of cell therapy drugs is extremely high. At present, the selling price of cell drugs already listed in Europe and America is millions of RMB, which discourages the majority of patients. In response to this situation, the world's first intelligent iPS cell production platform developed independently by Help Therapeutics has built the world's first independently developed AI intelligent cell product production line, which has broken through the long-standing production bottleneck of biopharmaceuticals and achieved a breakthrough in the entire cell production industry, upgrading the annual output of a single production line from the original manual operation of a few hundred to a few thousand to a single production line with an annual output of 100,000 people. It has made the biopharmaceutical production mode from labor-intensive into the biopharmaceutical industry 4.0 era, solved the pain point of insufficient talents in the biopharmaceutical industry, and made China reach the international leading level in the cellular pharmaceutical industry.

Help Therapeutics is committed to combining the domestic top biomedical technology with advanced Chinese intelligent manufacturing, promoting the integration of upstream, midstream and downstream resources of the entire biopharmaceutical industry, and fundamentally improving product quality and reducing pharmaceutical costs through the greater linkage advantages brought by industrial clusters. With the mission of reshaping health, the company actively responds to the call of "innovation-driven development towards a strong science and technology nation", reflecting "innovation is the first driving force leading development". We will implement the major decisions of the Party Central Committee and the State Council on science and technology, implement the innovation-driven development strategy, always put people's health in the first place, and seize the most direct and realistic interests of the people, so that more patients can afford advanced and good drugs.